Abbott Laboratories is a medical devices business based in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $113.91 – an increase of 1.42% over the previous week. Abbott Laboratories employs 114,000 staff and has a trailing 12-month revenue of around $41.2 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $113.91 |
|---|---|
| 52-week range | $98.72 - $120.37 |
| 50-day moving average | $115.27 |
| 200-day moving average | $110.58 |
| Wall St. target price | $130.62 |
| PE ratio | 33.769 |
| Dividend yield | $2.2 (2.12%) |
| Earnings per share (TTM) | $3.29 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $111.1 from 2025-01-15
| 1 week (2025-01-10) | -1.08% |
|---|---|
| 1 month (2024-12-17) | -1.93% |
| 3 months (2024-10-17) | -5.76% |
| 6 months (2024-07-17) | 6.13% |
| 1 year (2024-01-17) | -2.48% |
|---|---|
| 2 years (2023-01-17) | 2.01% |
| 3 years (2022-01-14) | 121.5768 |
| 5 years (2020-01-17) | 36.35% |
Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Abbott Laboratories shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1903. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.8 billion.
The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $41.2 billion |
|---|---|
| Operating margin TTM | 18.75% |
| Gross profit TTM | $23 billion |
| Return on assets TTM | 6.49% |
| Return on equity TTM | 14.84% |
| Profit margin | 13.99% |
| Book value | $22.94 |
| Market Capitalization | $192.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 49.56% of net profits
Recently Abbott Laboratories has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $2.2 per share.
While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.
Abbott Laboratories's most recent dividend payout was on 13 February 2025. The latest dividend was paid out to all shareholders who bought their shares by 14 January 2025 (the "ex-dividend date").
Abbott Laboratories's shares were split on a 10000:4798 basis on 1 January 2013 . So if you had owned 4798 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.
Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as $98.7197 up to $120.3684. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.722. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. .
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Features and fees to consider before you open an account with this trading platform.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2025.
A deep dive into the highlights and limitations of Robinhood.
This account boasts commission-free trades and no minimums but has a low cash sweep rate.